Jim, Great idea! Interesting biotech with prostate drug in the works. Downside protection to 2.90. Risky, but worth a speculative play. If the drug gets approved you keep $2.10. If it doesn't, it probably won't fall below $3.00 as they have other drugs in the works. Thanks.
about DNDN-
Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics that harness the immune system to fight cancer. Its product portfolio includes active cellular immunotherapy, monoclonal antibody, and small molecule product candidates to treat various cancers. The company's product candidates include Provenge (sipuleucel-T), an active cellular immunotherapy that is in FDA priority review status for the treatment of asymptomatic, metastatic, androgen-independent prostate cancer; and Neuvenge (lapuleucel-T), which has completed phase 1 clinical trials for the treatment of breast, ovarian, and colon cancers. Dendreon also has various products in preclinical studies, which include Trp-p8 for the treatment of lung, breast, prostate, and colon cancers; CEA for the treatment of breast, lung, and colon cancers; CA-9 (MN) for the treatment of kidney, colon, and cervical cancers; and Anti-Serine Protease for the treatment of multiple cancers. The company has collaborative agreements with Genentech, Inc. for the preclinical research, clinical development, and commercialization of products derived from trp-p8, an ion channel found in prostate cancer cells; and with Amgen Fremont, Inc. for the discovery, development, and commercialization of human monoclonal antibodies against a membrane-bound serine protease. Dendreon, formerly known as Activated Cell Therapy, Inc., was founded in 1992. The company is based in Seattle, Washington.
